We recently published a list of Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus. In this article, we are going to ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer ...

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, we are going to take a look at where Eli Lilly and Company (NYSE ...

Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.